ThinkEquity Doubles Price Target on Achillion (ACHN) to $20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Price: $0.79 --0%
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
ThinkEquity doubled its price target on Buy-rated Achillion Pharmaceuticals (NASDAQ: ACHN) from $10 to $20.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $9.72 yesterday.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $9.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Reiterates Hold Rating on Advance Auto Parts (AAP)
- Marriott International (MAR) PT Raised to $402 at Stifel
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $37 at BTIG
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
ThinkEquitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
